Clinical development of an anti-GPC-1 antibody for the treatment of cancer

Saikat Ghosh, Pie Huda, Nicholas Fletcher, Douglas Campbell, Kristofer Thurecht, Bradley Walsh

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


Introduction: Glypican-1 (GPC-1) is a heparan sulfate proteoglycan (HSPG) overexpressed in multiple cancers. Multiple studies indicate the prominence of this cancer biomarker with significant diagnostic and therapeutic potential. Recent advances in monoclonal antibody (mAb)-based biopharmaceuticals targeting GPC-1 show promise toward managing GPC-1-positive solid tumors clinically.

Areas covered: This review addresses GPC-1 targeting antibodies for cancer therapy, in preclinical and clinical development. Current and emerging development of different anti-GPC-1 antibody formats based on mechanism of action and application are also discussed.

Expert opinion: Clinical development of novel anti-GPC-1 antibody-based formats is still in its early days. Using the patented anti-GPC-1 Miltuximab® as a case study, we have made an attempt to illustrate a pathway for preclinical to clinical translation, which could be useful for newer GPC-1 targeting immunotherapy agents.

Original languageEnglish
Pages (from-to)603-613
Number of pages11
JournalExpert Opinion on Biological Therapy
Issue number5
Early online date31 Jan 2022
Publication statusPublished - 4 May 2022
Externally publishedYes


  • Monoclonal antibody
  • cancer therapy
  • glypican-1
  • immunotherapy
  • solid tumors


Dive into the research topics of 'Clinical development of an anti-GPC-1 antibody for the treatment of cancer'. Together they form a unique fingerprint.

Cite this